170 related articles for article (PubMed ID: 27488933)
1. Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients.
Kang G; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ; Kim HN; Lee J; Choi K; Shin HY; Kim JK; Jeong SW; Cho SH
Asia Pac J Clin Oncol; 2017 Feb; 13(1):53-60. PubMed ID: 27488933
[TBL] [Abstract][Full Text] [Related]
2. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Perwitasari DA; Wessels JA; van der Straaten RJ; Baak-Pablo RF; Mustofa M; Hakimi M; Nortier JW; Gelderblom H; Guchelaar HJ
Jpn J Clin Oncol; 2011 Oct; 41(10):1168-76. PubMed ID: 21840870
[TBL] [Abstract][Full Text] [Related]
3. A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.
Singh KP; Dhruva AA; Flowers E; Kober KM; Miaskowski C
Crit Rev Oncol Hematol; 2018 Jan; 121():51-61. PubMed ID: 29279099
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
Eliasen A; Dalhoff K; Mathiasen R; Schmiegelow K; Rechnitzer C; Schelde AB; Perwitasari DA; Tsuji D; Brok J
Crit Rev Oncol Hematol; 2020 May; 149():102939. PubMed ID: 32259776
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
6. Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
He H; Yin JY; Xu YJ; Li X; Zhang Y; Liu ZG; Zhou F; Zhai M; Li Y; Li XP; Wang Y; Zhou HH; Liu ZQ
Clin Ther; 2014 Aug; 36(8):1242-1252.e2. PubMed ID: 25012726
[TBL] [Abstract][Full Text] [Related]
7. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Navari RM
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2738-46. PubMed ID: 25838122
[TBL] [Abstract][Full Text] [Related]
8. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
9. Effects of Palonosetron on Nausea and Vomiting Induced by Multiple-Day Chemotherapy: A Retrospective Study.
Hamano H; Mitsuhashi C; Suzuki Y; Zamami Y; Tsujinaka K; Okada N; Niimura T; Hayama T; Imai T; Ishida S; Sakamoto K; Goda M; Takechi K; Yagi K; Chuma M; Horinouchi Y; Shinomiya K; Ikeda Y; Kirino Y; Nakamura T; Yanagawa H; Hamada Y; Ishizawa K
Biol Pharm Bull; 2021; 44(4):478-484. PubMed ID: 33790099
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting.
Kim KR; Kang G; Ki MS; Shim HJ; Hwang JE; Bae WK; Chung IJ; Kim JK; Jeong S; Cho SH
Biomed Res Int; 2015; 2015():523601. PubMed ID: 26421292
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of chemotherapy-induced nausea and vomiting.
Sugino S; Janicki PK
Pharmacogenomics; 2015 Jan; 16(2):149-60. PubMed ID: 25616101
[TBL] [Abstract][Full Text] [Related]
13. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
14. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
15. Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study.
Eliasen A; Kornholt J; Mathiasen R; Wadt K; Stoltze U; Brok J; Rechnitzer C; Schmiegelow K; Dalhoff K
Pharmacogenet Genomics; 2022 Feb; 32(2):72-78. PubMed ID: 34750329
[TBL] [Abstract][Full Text] [Related]
16. Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy.
Tsuji D; Matsumoto M; Kawasaki Y; Kim YL; Yamamoto K; Nakamichi H; Sahara Y; Makuta R; Yokoi M; Miyagi T; Itoh K
Cancer Chemother Pharmacol; 2021 Jan; 87(1):73-83. PubMed ID: 33099677
[TBL] [Abstract][Full Text] [Related]
17. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting.
Ho CL; Su WC; Hsieh RK; Lin ZZ; Chao TY
Jpn J Clin Oncol; 2010 Apr; 40(4):294-301. PubMed ID: 20026457
[TBL] [Abstract][Full Text] [Related]
19. Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Kim HJ; Shin SW; Song EK; Lee NR; Kim JS; Ahn JS; Yun HJ; Cho YH; Park KU; Kim SY; Jang JS; Kim SW; Lee HW; Lee SR; Kim YS; Lee SN; Ko YH; Kim HJ; Kang JH
Oncologist; 2015 Dec; 20(12):1440-7. PubMed ID: 26512046
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
Gamble M; Carroll E; Wright GC; Glode AE
J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
